The genetics of individuals with Down Syndrome have provided Flinders University researchers with a method to identify a single gene that may be responsible for defective insulin secretion in type 2 (acquired) diabetes.
Flinders cell physiologist Professor Damien Keating says a cross-referencing approach using genes from Down Syndrome individuals allowed collaborating international research teams to narrow down the candidates from a field of 5,000 candidate genes to one, known as RCAN1.
The results of the study, led by Professor Keating and involving researchers from Flinders, the US, Sweden and the UK, have just been published in the leading international journal PLOS Genetics.
Because Down Syndrome occurs when people have an extra copy of chromosome 21, they are prone to a range of health disorders resulting from the overexpression of particular genes: some people with Down Syndrome are diabetic from birth, Professor Keating says.
‘Many individuals with Down Syndrome experience lower insulin secretion, mitochondrial dysfunction and increased oxidative stress in the insulin-producing beta cells of the pancreas, which are all conditions that also appear in people with Type 2 diabetes,’ Professor Keating says.
To identify genes duplicated in Down Syndrome that contribute to problems with insulin secretion, scientists screened the genes of four mouse models of the disorder – two had high blood sugar and two did not, with the variation enabling a short-list of 38 implicated genes to be identified.
The scientists then narrowed down the list by comparing it to genes overexpressed in beta cells from humans with Type 2 diabetes.
‘The comparison identified a single gene, RCAN1, which, when we overexpress it in mice, causes them to have abnormal mitochondria in their beta cells, produce less cellular energy and secrete less insulin in the presence of high glucose,’ Professor Keating says.
Professor Keating says the results of the study not only explain why individuals with Down syndrome are more likely to have Type 1 diabetes, but reveal the function of a gene that may be playing a lead role in development of Type 2 diabetes in the general population.
‘We essentially developed this search approach associated with Down Syndrome to whittle down our candidates, came up with a lead candidate and then identified that it does cause a lot of the problems that we see in humans with Type 2 diabetes,’ he says.
Professor Keating says the discovery has clear clinical implications for the design of drug treatments to improve the function of beta cells in the pancreas.
And as well as identifying a target for anti-diabetes drugs, he says the approach has exciting potential to be used for other health disorders with symptoms that also appear in individuals with Down Syndrome, including heart conditions and Alzheimer’s disease.
(Source: Flinders University, PLOS Genetics)